thumbnail image
  • Home
  • Innovation 
    • Imuno TF®
    • ImmunoFormulation
  • Scientific evidences
  • Patient cases
  • Contact us
  • …  
    • Home
    • Innovation 
      • Imuno TF®
      • ImmunoFormulation
    • Scientific evidences
    • Patient cases
    • Contact us
  • Home
  • Innovation 
    • Imuno TF®
    • ImmunoFormulation
  • Scientific evidences
  • Patient cases
  • Contact us
  • …  
    • Home
    • Innovation 
      • Imuno TF®
      • ImmunoFormulation
    • Scientific evidences
    • Patient cases
    • Contact us
  • Patients Cases Reports

    Get to know the history of some patients that used Imuno TF® and associations (ImmunoFormulation®).

    Those cases are available in full here

    https://encyclopedia.pub/1999

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

  •  
    Case report

    Imuno TF® as a standalone supplement for periungual warts

    Background

    Periungual warts (PW), also known as verruca vulgaris, are caused by the human papillomavirus

    and appear as skin lesions located around the nail fold but can also affect the nail plate.

    Unfortunately, some of the therapies mentioned are destructive by nature and can also

    damage the nail matrix, hyponychium, or underlying bone.

     

    Case description

    Here we describe a patient resistant to a range of standard treatments.

    His clinical condition dramatically improved after the use of isolated transfer factors (TF).

     

    Conclusion

    As shown in this case, TF could be a possible effective alternative

    to treat therapy-resistant PW and we hope this report will lead to further investigation,

    including controlled trials with TF in this patient group.

    Check the article here

Together

we create the future

of personalizing medicine.

Contact Us

info@imunoline.com

Privacy policy

Cookies policy

Fagron© 2020

    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More